Dare Bioscience (DARE) Sets New 52-Week Low at $1.14

Dare Bioscience Inc (NASDAQ:DARE) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $1.14 and last traded at $1.12, with a volume of 478142 shares changing hands. The stock had previously closed at $1.22.

Separately, ValuEngine raised shares of Dare Bioscience from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 9th.

The stock has a market capitalization of $7.38, a price-to-earnings ratio of -0.51 and a beta of 2.68.

COPYRIGHT VIOLATION WARNING: This piece was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/03/13/dare-bioscience-dare-sets-new-52-week-low-at-1-14.html.

About Dare Bioscience

Dare Bioscience, Inc, formerly Cerulean Pharma Inc, is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse.

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply